Combined Placental Mesenchymal Stem Cells with Guided Nanoparticles Effective Against Diabetic Nephropathy in Mouse Model
Ke Wang,Te Liu,Yucheng Zhang,Huiying Lv,Hua Yao,Ye Zhao,Jing Li,Xiuying Li
DOI: https://doi.org/10.2147/ijn.s446733
IF: 7.033
2024-01-26
International Journal of Nanomedicine
Abstract:Ke Wang, 1, 2, &ast Te Liu, 1, &ast Yucheng Zhang, 1 Huiying Lv, 1 Hua Yao, 1 Ye Zhao, 3 Jing Li, 1 Xiuying Li 1 1 Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China; 2 Gynecology and Obstetrics Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China; 3 Dermatological Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiuying Li; Jing Li, Email ; Background: Diabetic nephropathy (DN) is a prevalent complication of diabetes mellitus and constitutes the primary cause of mortality in affected patients. Previous studies have shown that placental mesenchymal stem cells (PL-MSCs) can alleviate kidney dysfunction in animal models of DN. However, the limited ability of mesenchymal stem cells (MSCs) to home to damaged sites restricts their therapeutic potential. Enhancing the precision of PL-MSCs' homing to target tissues is therefore vital for the success of cell therapies in treating DN. Methods: We developed Fe 3 O 4 coated polydopamine nanoparticle (NP)-internalized MSCs and evaluated their therapeutic effectiveness in a mouse model of streptozotocin- and high-fat diet-induced DN, using an external magnetic field. Results: Our study confirmed that NPs were effectively internalized into PL-MSCs without compromising their intrinsic stem cell properties. The magnetic targeting of PL-MSCs notably improved their homing to the kidney tissues in mice with DN, resulting in enhanced kidney function compared to the transplantation of PL-MSCs alone. Furthermore, the anti-inflammatory and antifibrotic attributes of PL-MSCs played a role in the recovery of kidney function and structure. Conclusion: These results demonstrate that magnetically targeted therapy using PL-MSCs is a promising approach for treating diabetic nephropathy. Keywords: diabetic nephropathy, magnetic targeting, mesenchymal stem cells, iron oxide nanoparticles Diabetes is among the most prevalent diseases globally, and its incidence continues to rise. The complications associated with type 2 diabetes, along with the adverse reactions to antidiabetic treatments, significantly affect patients' quality of life and pose direct health risks. 1 Therefore, preventing and delaying diabetes-related complications are essential clinical objectives. 2,3 Diabetic nephropathy (DN), a primary chronic microvascular complication of diabetes, is a leading cause of end-stage renal disease. 4 Once DN progresses to end-stage kidney disease, its complex metabolic characteristics render it more challenging to treat compared to other kidney diseases. DN's key pathological features include glomerular sclerosis, thickening of the basement membrane, and mesangial dilation. Other features are apoptosis and loss of podocytes, renal interstitial inflammatory infiltration, and fibrosis. 5 Although drugs that lower blood sugar or blood pressure, along with angiotensin inhibitors, can delay the onset of DN, they cannot completely prevent it. 6 Presently, there is no cure for DN, making the exploration of novel, DN-specific treatment strategies imperative. Stem cell therapy represents an innovative approach for treating various diseases, potentially outperforming single-agent drug therapies. 7 Increasing evidence indicates that mesenchymal stem cells (MSCs) not only improve renal function 8 but also prevent the progression of DN 9,10 and reduce overt albuminuria. 11,12 Placental MSCs (PL-MSCs) are particularly promising due to their higher proliferation potential, differentiation capabilities, and lower immunogenicity compared to MSCs from other tissues. 13 For effective treatment, it is crucial to achieve efficient homing of MSCs to damaged tissues. 11 Generally administered intravenously, MSCs often show low uptake at injury sites, suggesting that enhancing their targeted homing capability could be a novel strategy to improve DN treatment efficacy. Magnetic targeting systems using magnetically labeled cells have proven more effective in cell delivery to injury sites than non-magnetic systems. 14,15 Recent studies demonstrate that external magnets can effectively guide magnetically labeled cells to specific locations in vivo, a process known as magnetic cell attraction. 16 Superparamagnetic iron oxide nanoparticles (NPs) are ideal for this purpose, attaching to a -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology